Advertisement

Topics

NICE recommends first overseas treatment for use on NHS with GSK 'bubble baby' gene therapy

05:59 EST 4 Jan 2018 | Pharmafile

NICE has chalked up a new first in its assessment of treatments for use on the NHS, ruling that the health service should fund GlaxoSmithKline’s gene therapy Strimvelis for the treatment of adenosine deaminase deficiency (ADA-SCID) – also known as ‘bubble baby syndrome’ – marking the first time the body has recommended a treatment which is currently only available in another country.

read more

Original Article: NICE recommends first overseas treatment for use on NHS with GSK 'bubble baby' gene therapy

NEXT ARTICLE

More From BioPortfolio on "NICE recommends first overseas treatment for use on NHS with GSK 'bubble baby' gene therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...